Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 3
1968 4
1971 5
1974 1
1975 1
1977 3
1978 2
1979 2
1980 1
1981 2
1982 3
1983 4
1984 8
1985 8
1986 5
1987 13
1988 2
1989 6
1990 2
1991 5
1992 3
1993 4
1994 7
1995 8
1996 11
1997 11
1998 15
1999 17
2000 19
2001 20
2002 45
2003 28
2004 18
2005 22
2006 24
2007 18
2008 24
2009 35
2010 24
2011 32
2012 32
2013 84
2014 64
2015 71
2016 75
2017 86
2018 60
2019 68
2020 73
2021 99
2022 97
2023 79
2024 71
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,232 results

Results by year

Filters applied: . Clear all
Page 1
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: saeki h. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink AE, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren RB, Simpson E, Reich K. Blauvelt A, et al. Among authors: saeki h. J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19. J Am Acad Dermatol. 2022. PMID: 35863467 Free article.
DNA replication stress and cancer chemotherapy.
Kitao H, Iimori M, Kataoka Y, Wakasa T, Tokunaga E, Saeki H, Oki E, Maehara Y. Kitao H, et al. Among authors: saeki h. Cancer Sci. 2018 Feb;109(2):264-271. doi: 10.1111/cas.13455. Epub 2017 Dec 22. Cancer Sci. 2018. PMID: 29168596 Free PMC article. Review.
The ability of biomarkers to assess the severity of atopic dermatitis.
Nakahara T, Onozuka D, Nunomura S, Saeki H, Takenaka M, Matsumoto M, Kataoka Y, Fujimoto R, Kaneko S, Morita E, Tanaka A, Saito R, Okano T, Miyagaki T, Aoki N, Nakajima K, Ichiyama S, Kido-Nakahara M, Tonomura K, Nakagawa Y, Tamagawa-Mineoka R, Masuda K, Takeichi T, Akiyama M, Ishiuji Y, Katsuta M, Kinoshita Y, Tateishi C, Yamamoto A, Morita A, Matsuda-Hirose H, Hatano Y, Kawasaki H, Fukushima-Nomura A, Ohtsuki M, Kamiya K, Kabata Y, Abe R, Mitsui H, Kawamura T, Tsuji G, Katoh N, Furue M, Izuhara K. Nakahara T, et al. Among authors: saeki h. J Allergy Clin Immunol Glob. 2023 Sep 27;3(1):100175. doi: 10.1016/j.jacig.2023.100175. eCollection 2024 Feb. J Allergy Clin Immunol Glob. 2023. PMID: 37915726 Free PMC article.
Recent advances in treatment for colorectal liver metastasis.
Oki E, Ando K, Nakanishi R, Sugiyama M, Nakashima Y, Kubo N, Kudou K, Saeki H, Nozoe T, Emi Y, Maehara Y. Oki E, et al. Among authors: saeki h. Ann Gastroenterol Surg. 2018 Apr 17;2(3):167-175. doi: 10.1002/ags3.12071. eCollection 2018 May. Ann Gastroenterol Surg. 2018. PMID: 29863162 Free PMC article. Review.
Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
Beck LA, Bieber T, Weidinger S, Tauber M, Saeki H, Irvine AD, Eichenfield LF, Werfel T, Arlert P, Jiang L, Røpke M, Paller AS. Beck LA, et al. Among authors: saeki h. J Am Acad Dermatol. 2023 Apr;88(4):816-823. doi: 10.1016/j.jaad.2022.11.047. Epub 2022 Dec 5. J Am Acad Dermatol. 2023. PMID: 36473633 Free article. Clinical Trial.
1,232 results